Innovative Insulin Combinations: A New strategy for the Person With T2DM.

Slides:



Advertisements
Similar presentations
What's New in Basal Insulin for Diabetes
Advertisements

Fig. 1. Study flow chart. Group A: intensifying oral hypoglycemic agents (OHAs; sulfonylurea+metformin dose titration or fixed-dose combination added to.
Case-Based Examination of Treatment Options in Type 2 Diabetes Management.
Endocrine Combinations in HR-Positive MBC: The Future Is Now
Short-, Intermediate-, Long-Acting Insulins
Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.
Applying Data to Practice
Atrial Fibrillation and PCI
Glaucoma Progression.
Modern Strategies for Basal Insulin Use in T2D
Patient Case Discussions in T2D: What Intensification Plan Is Best?
Insulin Innovation.
Insulin/GLP-1 Agonist Combinations
Program Goals. Consulting the Experts: Prandial Insulin or a GLP-1 Receptor Agonist as Add-On to Basal Insulin.
Insulin Intensification Strategies in Later-Stage Type 2 Diabetes Mellitus.
Agenda. Insulin Intensification Strategies: An Expert Perspective from Asia-Pacific.
Clinical Advances in Type 2 Diabetes and Cardiovascular Risk
Updates Abound.
Working as a Team for Improved Patient Outcomes in Type 2 Diabetes
What Do Primary Care Physicians Need to Know About Insulin/GLP-1 RA Fixed-Ratio Combinations?
Program Goals. What Will the Emerging Basal Insulin Products Mean for My Diabetes Practice?
Challenges in Managing Progressive Multiple Sclerosis
Emerging Basal Insulins for Diabetes
Insights into Insulin Treatment Challenges: Real-World Evidence and Clinical Trial Data.
GLP-1 Receptor Agonists: How Early Is Appropriate?
A New Chapter for CV Risk Management in Diabetes - Challenges & Opportunities.
The future of urate-lowering strategies for gout
Novel Insulin Combinations: What Does the Primary Care Physician Need to Know?
WHO Clinical Classification of PH Complex Cases in PH.
Integrated Diabetes Care: How Can We Make the Best Use of New Technology?
Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?
Insulin/GLP-1 Agonist Combinations
Insulin Use in Primary Care: Practice Challenges
Insulin Innovation.
Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients.
New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.
T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus
LEADER One Year On.
EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.
Better Diabetes Control With Novel Basal Insulins
Background. Advancing the Care of Patients With Moderate to Severe Atopic Dermatitis: A Case-Based Discussion.
Program Goals Overview Is NEDA a Reasonable Target?
Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?
Optimizing Insulin Therapy in Primary Care: Basal Plus Incretin Combinations.
Insulin Innovation.
Program Goals Disclaimers Defining Refractory Seizures.
Are We Making Progress in the Management of Huntington Disease?
Insulin in Diabetes Management: Effective Patient Selection Is Key
PEARLS OF WISDOM WITH COMBINATION THERAPY IN PAH
Oral Prostacyclin Pathway Agents in PAH
COMBINATIONS AND COFORMULATIONS: THE FUTURE OF INSULIN THERAPY?
Add-On Therapy to Insulin in T1DM Management
Incorporating Prostacyclins Into Practice
Introduction. Emerging Treatments for Thrombocytopenia in Adults With CLD Requiring Elective Invasive Procedures.
Improving Effective Basal Insulin Use in Clinical Practice
Clinical Challenges and Updates in Managing Seizure Clusters
Program Goals Overview Is NEDA a Reasonable Target?
Navigating New Treatment Landscapes in HR+ HER2-Negative Advanced Breast Cancer.
Prostacyclin Pathway Agents in Action
Emerging Combination Injectable Therapy A New Era in Diabetes Care
Introduction. Welcome to this program, titled De-Escalating Therapy in Epilepsy: A Return to Monotherapy.
Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.
Mitigating Side Effects and Optimizing Compliance With Oral Therapies in CLL.
Exploring the Use of Adeno-Associated Virus for Gene Therapy
Fixed-Ratio Combination Therapy in T2DM
Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.
The Expanding Role of SGLT Inhibitors Across the Diabetes Spectrum
Emerging Basal Insulins for Diabetes
Fresh perspectives ON BASAL Insulins in diabetes care
The Challenge of Insulin Titration
Presentation transcript:

Innovative Insulin Combinations: A New strategy for the Person With T2DM

Program Overview

Current Gaps in Insulin Therapy

The Role of Basal Insulin

Treatment Gaps Related to Titration

Patient-Led Titration of Insulin

Clinical Inertia

Intensification of Insulin

Premixed Insulins

Basal-Bolus Therapy

GLP-1 RA Mechanism of Action

Basal Insulin Plus GLP-1 RA—Free Combination

Basal Insulin/GLP-1 RA—Fixed-Ratio Combination

Formulations—Fixed-Ratio Basal Insulin/GLP-1 RA Combinations

DUAL V: Study Design

DUAL V: Key Results

DUAL V: Adverse Events

LixiLan-L Trial: Study Design

LixiLan-L Trial: Key Clinical Findings

LixiLan-L Trial: Key Clinical Findings (cont)

Potential Challenges With Fixed-Ratio Combinations

Fixed-Ratio Combination Basal Insulin/GLP-1 RA in Clinical Practice

Summary

Abbreviations